<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Secondary malignancies</z:e> including myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> occur infrequently in <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) and to the authors' knowledge have not been as well documented in adults as in children </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A total of 641 patients with de novo ALL who were treated with the hyper-CVAD (hyperfractionated <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>) regimen or its variants were analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Sixteen patients (2.49%) developed secondary <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (6 patients) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (10 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>At the time of ALL diagnosis, the median age was 53 years; cytogenetics were <z:mpath ids='MPATH_458'>normal</z:mpath> in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients </plain></SENT>
<SENT sid="4" pm="."><plain>Frontline therapy included hyper-CVAD in 7 patients, hyper-CVAD with rituximab in 8 patients, and hyper-CVAD with <z:chebi fb="0" ids="45783">imatinib</z:chebi> in 1 patient </plain></SENT>
<SENT sid="5" pm="."><plain>Karyotype at time of <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> diagnosis was -5, -7 in 9 patients, <z:mpath ids='MPATH_458'>normal</z:mpath> in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">Secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> developed at a median of 32 months after ALL diagnosis </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="28680">Cytarabine</z:chebi> plus <z:chebi fb="0" ids="48120">anthracycline</z:chebi>-based treatment was given to 12 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>One patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> received <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi>, 1 received clofarabine, and 2 received <z:chebi fb="0" ids="50131">decitabine</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated </plain></SENT>
<SENT sid="10" pm="."><plain>Eight patients (1 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 7 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) underwent allogeneic stem cell transplantation, and <z:hpo ids='HP_0000001'>all</z:hpo> but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation </plain></SENT>
<SENT sid="11" pm="."><plain>The median overall survival after a diagnosis of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was 9.25 months (range, 1+ to 26+ months) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">Secondary AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor </plain></SENT>
</text></document>